Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26795642 | 0.84 | IRAK4 (0.40) | IRAK4NLRP3CNR1HDAC1HDAC8 | |
| SCHEMBL159589 | 0.81 | ALDH1A1 (0.40) | NLRP3CNR2CNR1TBXA2RHDAC1 | |
| SCHEMBL22618722 | 0.80 | NPC1 (0.40) | IRAK4CNR1TBXA2RHDAC1HDAC8 | |
| SCHEMBL18232988 | 0.79 | HDAC1 (0.42) | NLRP3CNR2CNR1TBXA2RHDAC1 | |
| SCHEMBL23193123 | 0.79 | IRAK4 (0.38) | IRAK4CNR2CNR1HDAC1HDAC8 | |
| SCHEMBL20464221 | 0.79 | HDAC6 (0.39) | IRAK4CNR1TBXA2RHDAC1HDAC8 | |
| SCHEMBL8965333 | 0.78 | KDM4E (0.35) | IRAK4HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL17281398 | 0.78 | DAGLA (0.36) | IRAK4ALDH1A1 | |
| SCHEMBL20462599 | 0.78 | NPC1 (0.43) | IRAK4TBXA2RALDH1A1LMNAMAOB | |
| SCHEMBL77505 | 0.77 | DAGLA (0.40) | IRAK4NLRP3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | HAVCR2, ZC3HAV1, SLC10A1 | IRAK4 3035/4885NLRP3 3204/4885CNR2 2387/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | IRAK4 3035/4885NLRP3 3204/4885CNR2 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.